
Sign up to save your podcasts
Or


At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.
In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.
From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4
1111 ratings
At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.
In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.
From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.

30,860 Listeners

3,234 Listeners

964 Listeners

1,987 Listeners

1,655 Listeners

1,090 Listeners

335 Listeners

1,051 Listeners

227 Listeners

6,093 Listeners

35 Listeners

150 Listeners

21 Listeners

77 Listeners

142 Listeners